TY - JOUR
T1 - Serum lysophospholipase D/autotaxin may be a new nutritional assessment marker
T2 - Study on prostate cancer patients
AU - Nakamura, Kazuhiro
AU - Takeuchi, Takumi
AU - Ohkawa, Ryunosuke
AU - Okubo, Shigeo
AU - Yokota, Hiromitsu
AU - Tozuka, Minoru
AU - Aoki, Junken
AU - Arai, Hiroyuki
AU - Ikeda, Hitoshi
AU - Ohshima, Noriko
AU - Kitamura, Tadaichi
AU - Yatomi, Yutaka
PY - 2007/1/11
Y1 - 2007/1/11
N2 - Background: It is now established that the bioactive lipid lysophosphatidic acid (LPA) contributes to cancer initiation, progression and metastasis, including those of prostate cancer. LPA is produced in the serum and plasma mainly by conversion from lysophospholipids through the action of lysophospholipase D (lysoPLD), which is identical to the soluble form of autotaxin (ATX) originally isolated as a tumour cell motility-stimulating factor. In this study, we evaluated the usefulness of lysoPLD/ATX activity as a diagnostic marker. Methods: The serum lysoPLD activity, assessed by measuring choline liberation from the substrate lysophosphatidylcholine, was measured in patients with prostate cancer and compared with the concentrations of prostate-specific antigen (PSA) and conventional nutritional assessment markers. Results: The serum lysoPLD activity in prostate cancer patients was not statistically different from that in the controls. Consistent with this, there was no correlation between the serum lysoPLD activity and the serum PSA concentrations. However, the lysoPLD/ATX activity did decrease after operation in the prostate cancer patients and seemed to reflect the postoperative damage or the nutritional status. Conclusions: We postulate that while the serum lysoPLD/ATX may not be a marker of prostate cancer, it promises to instead be a new marker of nutritional status.
AB - Background: It is now established that the bioactive lipid lysophosphatidic acid (LPA) contributes to cancer initiation, progression and metastasis, including those of prostate cancer. LPA is produced in the serum and plasma mainly by conversion from lysophospholipids through the action of lysophospholipase D (lysoPLD), which is identical to the soluble form of autotaxin (ATX) originally isolated as a tumour cell motility-stimulating factor. In this study, we evaluated the usefulness of lysoPLD/ATX activity as a diagnostic marker. Methods: The serum lysoPLD activity, assessed by measuring choline liberation from the substrate lysophosphatidylcholine, was measured in patients with prostate cancer and compared with the concentrations of prostate-specific antigen (PSA) and conventional nutritional assessment markers. Results: The serum lysoPLD activity in prostate cancer patients was not statistically different from that in the controls. Consistent with this, there was no correlation between the serum lysoPLD activity and the serum PSA concentrations. However, the lysoPLD/ATX activity did decrease after operation in the prostate cancer patients and seemed to reflect the postoperative damage or the nutritional status. Conclusions: We postulate that while the serum lysoPLD/ATX may not be a marker of prostate cancer, it promises to instead be a new marker of nutritional status.
UR - http://www.scopus.com/inward/record.url?scp=40349103842&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=40349103842&partnerID=8YFLogxK
U2 - 10.1258/000456307782268147
DO - 10.1258/000456307782268147
M3 - Article
C2 - 17961310
AN - SCOPUS:40349103842
VL - 44
SP - 549
EP - 556
JO - Annals of Clinical Biochemistry
JF - Annals of Clinical Biochemistry
SN - 0004-5632
IS - 6
ER -
